Home > Insider Trading > Filing (0001209191-16-129177)

Filing Details

Accession Number:: 0001209191-16-129177
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2016-06-22 13:36:49
Reporting Period:: 2016-06-20

Filing Date:: 2016-06-22
Accepted Time:: 2016-06-22 13:36:49
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1419600	Flexion Therapeutics Inc	FLXN	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1201580	D Samuel Colella	C/O Flexion Therapeutics, Inc. 10 Mall Road, Suite 301 Burlington MA 01803		Yes	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2016-06-20	3,435	$13.98	3,435	No	4	P	Direct
Common Stock	Acquisiton	2016-06-20	3,343	$13.70	6,778	No	4	P	Direct
Common Stock	Acquisiton	2016-06-21	13,222	$13.62	20,000	No	4	P	Direct
Common Stock	Acquisiton	2016-06-21	4,600	$13.76	24,600	No	4	P	Direct
Common Stock	Acquisiton	2016-06-21	504	$13.65	25,104	No	4	P	Direct
Common Stock	Acquisiton	2016-06-21	400	$13.71	25,504	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	3,511,670	Indirect	See Footnote
Common Stock	20,739	Indirect	See Footnote
Common Stock	388,683	Indirect	See Footnote

Footnotes

The weighted average sale price for the transaction reported was $13.9796206, and the range of prices were between $13.965 and $14.00. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.
The weighted average sale price for the transaction reported was $13.7043, and the range of prices were between $13.34 and $13.99. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.
The weighted average sale price for the transaction reported was $13.6223, and the range of prices were between $13.41 and $14.175. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.
The weighted average sale price for the transaction reported was $13.7583, and the range of prices were between $13.65 and $13.82. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.
The weighted average sale price for the transaction reported was $13.6523, and the range of prices were between $13.62 and $13.69. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.
The weighted average sale price for the transaction reported was $13.7078, and the range of prices were between $13.701546 and $13.71. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.
The shares are held by Versant Venture Capital III, L.P. ("VVC III"). The Reporting Person is a managing member of Versant Ventures III, LLC ("VV III"), the sole general partner of VVC III and shares voting and dispositive power over the shares held by VVC III; however, he disclaims beneficial ownership of the shares held by such entity except to the extent of his pecuniary interests therein.
The shares are held by Versant Side Fund III, L.P. ("Side Fund III"). The Reporting Person is a managing member of VV III, the sole general partner of Side Fund III and shares voting and dispositive power over the shares held by Side Fund III; however, he disclaims beneficial ownership of the shares held by such entity except to the extent of his pecuniary interests therein.
The shares are held by Versant Development Fund III, LLC ("Development III"). The Reporting Person is a managing member of VV III, a majority member of Development III and shares voting and dispositive power over the shares held by Development III; however, he disclaims beneficial ownership of the shares held by such entity except to the extent of his pecuniary interests therein.